Literature DB >> 19177752

[Mechanisms of high-risk human papillomavirus-induced cervical carcinogenesis].

Mako Narisawa-Saito1, Tohru Kiyono.   

Abstract

Human papillomaviruses (HPVs) are believed to be the primary causal agents for development of pre-neoplastic and malignant lesions of the uterine cervix and high-risk types such as type 16 and 18 are associated with more than 90% of all cervical carcinomas. The E6 and E7 genes of HPVs are thought to play causative roles, since E6 promotes the degradation of p53 through its interaction with E6AP, an E3 ubiquitin ligase, whereas E7 binds to the retinoblastoma protein pRb and disrupts its complex formation with E2F transcription factors. Although prophylactic vaccines have become available, it is still necessary to clarify the mechanisms of HPV-induced carcinogenesis because of the widespread nature of HPV infection. In this article, the mechanisms of high-risk HPV E6 and E7-induced multistep carcinogenesis and recently identified functions of these oncoproteins are reviewed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19177752

Source DB:  PubMed          Journal:  Nihon Rinsho        ISSN: 0047-1852


  3 in total

1.  Activation of the interleukin-32 pro-inflammatory pathway in response to human papillomavirus infection and over-expression of interleukin-32 controls the expression of the human papillomavirus oncogene.

Authors:  Sojung Lee; Jung-Hee Kim; Heejong Kim; Jeong Woo Kang; Soo-Hyun Kim; Young Yang; Jinman Kim; JongSup Park; SurNie Park; JinTae Hong; Do-Young Yoon
Journal:  Immunology       Date:  2011-01-05       Impact factor: 7.397

2.  Small Circular DNAs in Human Pathology.

Authors:  Stephany Carolina Barreto; Madhuri Uppalapati; Amitabha Ray
Journal:  Malays J Med Sci       Date:  2014-05

3.  Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy.

Authors:  Kim E Kortekaas; Saskia J Santegoets; Liselotte Tas; Ilina Ehsan; Pornpimol Charoentong; Helena C van Doorn; Mariette I E van Poelgeest; Dana A M Mustafa; Sjoerd H van der Burg
Journal:  J Immunother Cancer       Date:  2021-10       Impact factor: 13.751

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.